Works Cited

Viral Diseases: Oral Involvement and Complications

Course #54983 - $30 • 5 Hours/Credits

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

1. Hunt M. Basic Virology: Replication of Viruses. Available at http://www.microbiologybook.org/mhunt/replicat.htm. Last accessed March 24, 2020.

2. Golla K, Epstein JB, Cabay RJ. Liver disease: current perspectives on medical and dental management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98(5):516-521.

3. Little JW, Falace DA, Miller C, Rhodus NL. Little and Falace's Dental Management of the Medically Compromised Patient. 9th ed. St. Louis, MO: Mosby, Inc.; 2018.

4. Takahashi M, Kuusakai S, Mizuo H, et al. Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) is highly specific for diagnosis of acute HEV infection. J Clin Microbiol. 2005;43(1):49-56.

5. Shetty K, Husain KM. Hepatitis A-G: review for the general dental practitioner. J Greater Houston Dental Soc. 2007;79(5):12-21.

6. Centers for Disease Control and Prevention. Hepatitis A: General Information. Available at https://www.cdc.gov/hepatitis/hav/pdfs/hepageneralfactsheet.pdf. Last accessed March 24, 2020.

7. Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. Available at https:// www.cdc.gov/hepatitis/HAV/HAVfaq.htm. Last accessed March 24, 2020.

8. Centers for Disease Control and Prevention. Hepatitis B: General Information. Available at https://www.cdc.gov/hepatitis/HBV/PDFs/HepBGeneralFactSheet.pdf. Last accessed March 24, 2020.

9. Molinari JA. What is the significance for dental professionals of the recently documented case of patient-to-patient transmission of hepatitis B? J Canadian Dent Assoc. 2007;73(10):911-912.

10. Redd JT, Baumbach J, Kohn W, Nainan O, Khristova M, Williams I. Patient-to-patient transmission of hepatitis B virus associated with oral surgery. J Infect Dis. 2007;195(9):1311-1314.

11. Occupational Health and Safety Administration. OSHA Fact Sheet: Hepatitis B Vaccination Protection. Available at https://www.osha.gov/OshDoc/data_BloodborneFacts/bbfact05.pdf. Last accessed March 24, 2020.

12. Centers for Disease Control and Prevention. Hepatitis B FAQs for Health Professionals. Available at https://www.cdc.gov/hepatitis/HBV/HBVfaq.htm. Last accessed March 24, 2020.

13. Thoelen S, Van Damme P, Leentvaar-Kuypers, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine. 1999;17(13-14):1657-1662.

14. Wynn RL, Meiller TF, Crossley HL. Drug Information Handbook for Dentistry. 25th ed. Hudson, OH: Lexi-Comp; 2019.

15. Hezard N, Metz D, Nazeyrollas P, et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents. Thromb Haemost. 2000;83:540-544.

16. Malamed SF. Handbook of Local Anesthesia. 6th ed. St. Louis, MO: Mosby, Inc.; 2012.

17. Centers for Disease Control and Prevention. Hepatitis D. Available at https://www.cdc.gov/hepatitis/HDV/index.htm. Last accessed March 24, 2020.

18. Centers for Disease Control and Prevention. Hepatitis C. FAQs for Health Professionals. Available at https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Last accessed March 24, 2020.

19. Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Diseases. 2008;14(1):10-14.

20. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. 2001;50(RR-5):1-43.

21. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998;47(RR19):1-39.

22. Husain N, Neyaz A. Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts.J Oral Biol Craniofac Res. 2017;7(3):198-205.

23. Hepatitis C Online. Hepatitis C Treatments: FDA-Approved. Available at https://www.hepatitisc.uw.edu/page/treatment/drugs. Last accessed March 24, 2020.

24. Lexi-Comp Online. Available at https://online.lexi.com/lco . Last accessed March 24, 2020.

25. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Last accessed March 24, 2020.

26. Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribavirin. J Gastroenterol Hepatol. 2000;15(6):581-586.

27. Centers for Disease Control and Prevention. Hepatitis E FAQs for Health Professionals. Available at https://www.cdc.gov/hepatitis/HEV/HEVfaq.htm. Last accessed March 24, 2020.

28. Centers for Disease Control and Prevention. HIV Surveillance Report, 2018. Available at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-vol-30.pdf. Last accessed March 24, 2020.

29. Fauci AS, Lane HC. HIV disease: AIDS and related disorders. In: Harrison's Online Principles of Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.

30. Silverman S Jr. Color Atlas of Oral Manifestations of AIDS. 2nd ed. St. Louis, MO: Mosby, Inc.; 1996.

31. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Last accessed March 24, 2020.

32. Newman MG, van Winkelhoff AJ. Antibiotic and Antimicrobial Use in Dental Practice. 2nd ed. New York, NY: Quintessence Publishing Co, Inc.; 2001.

33. Centers for Disease Control and Prevention. Shingles (Herpes Zoster). Available at https://www.cdc.gov/shingles/hcp/clinical-overview.html. Last accessed March 24, 2020.

34. Topazian RG, Goldberg MH, Hupp JR. Oral and Maxillofacial Infections. 4th ed. Philadelphia, PA: W.B. Saunders Co.; 2002.

35. Johns Hopkins Medicine. Epstein-Barr Virus. Available at https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545067/all/Epstein_Barr_virus. Last accessed March 24, 2020.

36. Godshall S, Kirchner J. Infectious mononucleosis: complexities of a common syndrome. Postgrad Med. 2000;107(7):175-179, 183-184, 186.

37. Bailey R. Diagnosis and treatment of infectious mononucleosis. Am Fam Physician. 1994;49(4):879-888.

38. Centers for Disease Control and Prevention. Epstein-Barr Virus and Infectious Mononucleosis. Available at https://www.cdc.gov/epstein-barr/about-mono.html. Last accessed March 24, 2020.

39. Centers for Disease Control and Prevention. Epstein-Barr Virus and Infectious Mononucleosis: References and Resources. Available at https://www.cdc.gov/epstein-barr/references.html. Last accessed March 24, 2020.

40. Tyring S (ed). Mucosal Immunology and Virology. London: Springer-Verlag; 2006.

41. Lynch DP. Hairy Leukoplakia. Available at https://emedicine.medscape.com/article/279269-overview. Last accessed March 24, 2020.

42. Glick M (ed). Clinician's Guide to Treatment of HIV-Infected Patients. 3rd ed. Baltimore, MD: American Academy of Oral Medicine; 2001.

43. New York State Department of Health AIDS Institute. Primary Care for People Living with HIV. Available at https://www.health.ny.gov/diseases/aids/providers/standards/support_services_providers/docs/primary_care.pdf. Last accessed March 24, 2020.

44. Burkitt DP. The discovery of Burkitt's lymphoma. Cancer. 1983;51(10):1777-1786.

45. Kanbar AH. Burkitt Lymphoma and Burkitt-Like Lymphoma. Available at https://emedicine.medscape.com/article/1447602-overview. Last accessed March 24, 2020.

46. Kasamon YL, Swinnen LJ. Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol. 2004;16(5):429-435.

47. Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and Congenital CMV Infection. Available at https://www.cdc.gov/cmv/overview.html. Last accessed March 24, 2020.

48. Syrjanen S, Leimola-Virtanen R, Schmidt-Westerhausen A, Reichart PA. Oral ulcers in AIDS patients frequently associated with cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection. J Oral Pathol Med. 1999;28(5):204-209.

49. Glick M, Cleveland DB, Salkin LM, Alfaro-Miranda M, Fielding AF. Intra-oral cytomegalovirus and HIV-associated periodontitis in a patient with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol. 1991;72(6):716-720.

50. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med. 1995;332:1181-1185.

51. Rose LJ. Kaposi Sarcoma. Available at https://emedicine.medscape.com/article/279734-overview. Last accessed March 24, 2020.

52. Lucatorto FM, Sapp JP. Treatment of oral Kaposi's sarcoma with a sclerosing agent in AIDS patients: a preliminary study. Oral Surg Oral Med Oral Pathol. 1993;75(2):192-198.

53. Stebbing J, Portsmouth S, Gazzard B. How does HAART lead to the resolution of Kaposi's sarcoma? J Antimicrob Chemother. 2003;51(5):1095-1098.

54. Schiødt M. HIV-associated salivary gland disease: a review. Oral Surg Oral Med Oral Pathol. 1992;73(2):164-167.

55. Tiwari A, Kini H, Pai RR, Rau AR. HIV lymphadenitis of the salivary gland: a case with cytological and histological correlation. J Cytol. 2009:26(4):146-148.

56. Lacovou E, Vlastarakos PV, Papacharalampous G, Kampessis G, Nikolopoulos TP. Diagnosis and treatment of HIV-associated manifestations in otolaryngology. Infect Dis Rep. 2012;4(1):e9.

57. Mandel L, Vakkas J. Parotid enlargement in patient with HIV. N Y State Dent J. 2005;71(1):44-46.

58. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians. 1999;111(6):581-587.

59. Eversole LR. Papillary lesions of the oral cavity: relationship to human papillomaviruses. J Calif Dent Assoc. 2000;28(12):922-927.

60. Scully C, Epstein J, Porter S, Cox M. Viruses and chronic disorders involving the human oral mucosa. Oral Surg Oral Med Oral Pathol. 1991;72(5):537-544.

61. Ghadishah D. Genital Warts. Available at https://emedicine.medscape.com/article/763014-overview. Last accessed March 25, 2020.

62. Kellokoski J, Syrjanen S, Syrjanen K, Yliskoski M. Oral mucosal changes in women with genital HPV infection. J Oral Pathol Med. 1990;19(3):142-148.

63. Eversole LR, Laipis PJ. Oral squamous papillomas: detection of HPV DNA by in situ hybridization. Oral Surg Oral Med Oral Pathol. 1988;65(5):545-550.

64. Scully C, Flint SR, Porter SR. Oral Diseases. 2nd ed. St. Louis, MO: Mosby, Inc.; 1996.

65. Harris AM, van Wyk CW. Heck's disease (focal epithelial hyperplasia): a longitudinal study. Community Dent Oral Epidemiol. 1993;21(2):82-85.

66. Padayachee A, van Wyk CW. Human papillomavirus (HPV) DNA in focal epithelial hyperplasia by in situ hybridization. J Oral Pathol Med. 1991;20(5):210-214.

67. University of California, San Francisco. Oral Manifestations of HIV. Available at http://hivinsite.ucsf.edu/InSite?page=kb-04-01-14#S3.3X. Last accessed March 25, 2020.

68. Centers for Disease Control and Prevention. HPV and Cancer. Available at https://www.cdc.gov/cancer/hpv/basic_info. Last accessed March 25, 2020.

69. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinoma worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.

70. Centers for Disease Control and Prevention. Measles (Rubeola): For Travelers. Available at https://www.cdc.gov/measles/travelers.html. Last accessed March 25, 2020.

71. Chen SSP. Measles. Available at https://emedicine.medscape.com/article/966220-overview. Last accessed March 25, 2020.

72. Centers for Disease Control and Prevention. Measles (Rubeola): Signs and Symptoms. Available at https://www.cdc.gov/measles/about/signs-symptoms.html. Last accessed March 25, 2020.

73. Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Parental vaccine safety concerns in 2009. Pediatrics. 2010;125(4):654-659.

74. Centers for Disease Control and Prevention. Measles (Rubeola): For Healthcare Professionals: Treatment. Available at https://www.cdc.gov/measles/hcp/index.html. Last accessed March 25, 2020.

75. World Health Organization. Weekly Epidemiological Rec. 2009;35(84):349-360.

76. Centers for Disease Control and Prevention. Update: mumps outbreak––New York and New Jersey, June 2009–January 2010. MMWR. 2010;59(5):125-129.

77. Defendi GL. Mumps. Available at https://reference.medscape.com/article/966678-overview. Last accessed March 25, 2020.

78. Ito M, Go T, Okuno T, Mikawa H. Chronic mumps virus encephalitis. Pediatr Neurol. 1991;7(6):467-470.

79. Hooi PS, Chua BH, Lee CS, Lam SK, Chua KB. Hand, foot, and mouth disease: University of Malaya Medical Centre experience. Med J Malaysia. 2002;57(1):88-91.

80. Centers for Disease Control and Prevention. Hand, Foot, and Mouth Disease (HFMD). Available at https://www.cdc.gov/hand-foot-mouth/about/index.html. Last accessed March 25, 2020.

81. Gompf SG. Herpangina. Available at https://emedicine.medscape.com/article/218502-overview. Last accessed March 24, 2020.

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.